Lyell Immunopharma Inc. (LYEL)
NASDAQ: LYEL
· Real-Time Price · USD
17.75
1.94 (12.27%)
At close: Oct 03, 2025, 3:59 PM
17.99
1.35%
After-hours: Oct 03, 2025, 07:29 PM EDT
12.27% (1D)
| Bid | 17.01 |
| Market Cap | 341M |
| Revenue (ttm) | 60K |
| Net Income (ttm) | -331.4M |
| EPS (ttm) | -24.72 |
| PE Ratio (ttm) | -0.72 |
| Forward PE | -1.44 |
| Analyst | Hold |
| Dividends | n/a |
| Ask | 17.94 |
| Volume | 56,906 |
| Avg. Volume (20D) | 54,715 |
| Open | 15.85 |
| Previous Close | 15.81 |
| Day's Range | 15.79 - 17.78 |
| 52-Week Range | 7.65 - 30.00 |
| Beta | -0.08 |
| Ex-Dividend Date | n/a |
About LYEL
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol LYEL
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for LYEL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 months ago
+19.31%
Lyell Immunopharma shares are trading higher after...
Unlock content with
Pro Subscription
11 months ago
+19.35%
Lyell Immunopharma shares are trading higher. The stock may be moving on continued strength after the company announced yesterday it will present clinical data from its Phase 1-2 trial of IMPT-314 CAR T-cell therapy for B-cell lymphoma at ASH 2024.
2 months ago · seekingalpha.com
Lyell: 'Hold' Rating Based On Phase 3 LYL314 LBCL Treatment Program AdvancementLyell Immunopharma's LYL314 CAR-T therapy shows high, durable response rates in 3rd-line + Large B-Cell Lymphoma patients. The company has initiated a phase 3 trial for LYL314 in 3rd-line + LBCL follo...